Daily Market Reports | 10:30 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
ACL ASK COV CSC FFM HSN JDO KYP PPL QAL SEK SGM SHA SRG SXE SYL TNE
ACL AUSTRALIAN CLINICAL LABS LIMITED
Healthcare services - Overnight Price: $2.20
Canaccord Genuity rates ((ACL)) as Downgrade to Hold from Buy (3) -
Australian Clinical Labs posted first half results that missed Canaccord Genuity's forecasts. The broker suspects the miss, and the downgrade to FY26 guidance, primarily relate to marginal share losses.
Underlying EBIT guidance has been downgraded by -3.5%, further exacerbated by additional operating expenditure stemming from the FWC review of gender undervaluation.
The pathology demand environment is not strong enough to allow the company's operating model and strategy to be differentiated from listed competitors and drive a re-rating, in the broker's opinion.
Rating is downgraded to Hold from Buy. Target is reduced to $2.40 from $3.85.
This report was published on February 17, 2026.
Target price is $2.40 Current Price is $2.20 Difference: $0.2
If ACL meets the Canaccord Genuity target it will return approximately 9% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 10.00 cents and EPS of 17.00 cents.
At the last closing share price the estimated dividend yield is 4.55%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.94.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 11.00 cents and EPS of 18.00 cents.
At the last closing share price the estimated dividend yield is 5.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.22.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ASK ABACUS STORAGE KING
REITs - Overnight Price: $1.51
Jarden rates ((ASK)) as Downgrade to Overweight from Buy (2) -
After further analysis of Abacus Storage King's interim results, Jarden lowers its target to $1.60 from $1.65 and maintains an Overweight rating.
A summary of the broker's initial research follows.
On first inspection, Jarden notes Abacus Storage King' 1H26 result was slightly softer than expected at the earnings line.
Funds from operations came in at 3.12c versus 3.4c for Jarden and 3.3c consensus, with established portfolio RevPAM growth of 1.5% considered weak relative to portfolio quality, while occupancy eased to 90.5% and WACR to 5.42%.
FY26 distribution guidance was maintained at 6.2c, in line with both Jarden and consensus expectations.
Jarden highlights potential investor focus on funding costs and internalisation progress, amid shifting rate expectations and sector M&A activity.
This report was published on February 17, 2026.
Target price is $1.60 Current Price is $1.51 Difference: $0.09
If ASK meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $1.58, suggesting upside of 4.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 6.20 cents and EPS of 6.50 cents.
At the last closing share price the estimated dividend yield is 4.11%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 23.23.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.5, implying annual growth of -70.5%.
Current consensus DPS estimate is 6.2, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 23.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 6.30 cents and EPS of 6.60 cents.
At the last closing share price the estimated dividend yield is 4.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 22.88.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.8, implying annual growth of 4.6%.
Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 22.2.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
COV CLEO DIAGNOSTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.59
Petra Capital rates ((COV)) as Buy (1) -
Petra Capital highlights Cleo Diagnostics’ selection of Nasdaq-listed Bio-Techne as manufacturer for its ovarian cancer test kits and the choice of Bio-Techne’s Ella platform as a key de-risking milestone.
The broker notes the platform's automated, multiplex capability and sub-90-minute turnaround as commercially attractive for pathology labs. Recent regulatory CE-IVD marking for diagnostic device compliance is also expected to support regulatory pathways.
Management expects a binding agreement later this quarter to enable analytical validation and pivotal trial sample testing ahead of an FDA 510(k) submission.
Buy. Target $1.26.
This report was published on February 18, 2026.
Target price is $1.26 Current Price is $0.59 Difference: $0.67
If COV meets the Petra Capital target it will return approximately 114% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE